| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
208.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $22.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gut Robert |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.70 |
$26,753 |
D/D |
(1,602) |
35,085 |
|
-34% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
10,877 |
|
-34% |
|
| Kaye Jack |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.76 |
$10,056 |
D/D |
(600) |
19,003 |
|
-34% |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2022-02-28 |
4 |
S |
$16.68 |
$24,753 |
D/D |
(1,484) |
122,325 |
|
-34% |
|
| Meek David D. |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
7,380 |
|
-34% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2022-02-28 |
4 |
S |
$16.80 |
$68,460 |
D/D |
(4,075) |
106,375 |
|
-34% |
|
| Soteropoulos Paula |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.87 |
$10,055 |
D/D |
(596) |
7,302 |
|
-34% |
|
| Balachandran Madhavan |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
10,877 |
|
-34% |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2022-02-28 |
4 |
S |
$16.72 |
$56,932 |
D/D |
(3,405) |
95,156 |
|
-34% |
|
| Kapusta Matthew C |
CEO & Managing Director |
• • – |
2022-02-28 |
4 |
S |
$16.70 |
$170,257 |
D/D |
(10,195) |
360,554 |
|
-34% |
|
| Post Leonard E |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.64 |
$13,229 |
D/D |
(795) |
3,121 |
|
-34% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
1,534 |
|
- |
|
| Gut Robert |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
36,687 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
7,898 |
|
- |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
54,683 |
123,809 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
19,603 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
11,479 |
|
- |
|
| Post Leonard E |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
3,916 |
|
- |
|
| Meek David D. |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
7,982 |
|
- |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
37,086 |
72,086 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
11,479 |
|
- |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,904 |
98,601 |
|
- |
|
| Kapusta Matthew C |
CEO and Managing Director |
• • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
125,073 |
370,749 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,630 |
110,450 |
|
- |
|
| Gut Robert |
Director |
– • – |
2022-01-26 |
4 |
S |
$18.12 |
$42,546 |
D/D |
(2,348) |
35,153 |
|
16% |
|
336 Records found
|
|
Page 4 of 14 |
|
|
0.01 (0.21%) 
